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Abstract
Increasing healthcare costs worldwide put the current healthcare systems under pressure. Although 
many efforts have aimed to contain costs in medicine, only a few have achieved substantial changes. 
Inflammatory bowel diseases rank among the most costly of chronic diseases, and physicians 
nowadays are increasingly engaged in health economics discussions. Value-based health care 
[VBHC] has gained a lot of attention recently, and is thought to be the way forward to contain 
costs while maintaining quality. The key concept behind VBHC is to improve achieved outcomes 
per encountered costs, and evaluate performance accordingly. Four main components need to be 
in place for the system to be effective: [1] accurate measurement of health outcomes and costs; 
[2] reporting of these outcomes and benchmarking against other providers; [3] identification of 
areas in need of improvement based on these data and adjusting the care delivery processes 
accordingly; and [4] rewarding high-performing participants. In this article we will explore the 
key components of VBHC, we will review available evidence focussing on inflammatory bowel 
diseases, and we will present our own experience as a guide for other providers.
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1. Introduction
Worldwide, healthcare costs continue to increase at an alarming 
pace. Despite differences in care delivery and financial infrastruc-
ture, most countries cope with similar trends of increasing health 
expenditures. It seems to be a universal ‘unsolvable’ problem 
[Figure 1a]. Disturbingly, the expenditure increase is not consist-
ently accompanied by an increase in quality and improved health 
outcomes [Figure  1b].1 Various factors contribute to the prob-
lem: ineffective care delivery, excessive administration costs, non-
adherence to guidelines, uncoordinated care, practise of defensive 
medicine, lack of preventive care, and introduction of new tech-
nologies.2 One overarching notion that has emerged is that neces-
sary preventive care is underdelivered, whereas unnecessary care 
is overdelivered. Indeed, due to current ‘fee-for-service’ payment 
structures, physicians are incentivized to often deliver more care 
than is necessary. Patients are usually unaware since there is little 
reporting on quality and health outcomes by individual physicians 
or hospitals.
Though reforms have addressed one or more of the aforemen-
tioned items, none has managed to achieve substantial savings that 
bend the overall cost curve. Solutions to reduce healthcare spending 
have frequently involved shifting costs around among participants: 
shifting costs from insurers to patients by increasing the annual pre-
miums; shifting costs between insurers; or shifting costs towards 
providers by introducing capitation payments. However, shifting 
costs around has not resulted in decreased overall spending in any 
way.3 Recently, it has become accepted that a complete care rede-
sign, involving all stakeholders, is warranted to solve the healthcare 
crisis. Moreover, the right incentives should be put in place for all 
participants in order to ensure sustainability. An area which is rap-
idly gaining ground is the area of ‘value-based health care’ [VBHC] 
which focuses solely on achieved health outcomes and associated 
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cost-effectiveness. This review introduces the concepts and ration-
ale behind VBHC and provides early results observed in the care of 
patients with inflammatory bowel diseases [IBD].
2. Value-Based Health Care
The main concept of VBHC is to evaluate health outcomes and their 
associated costs at the condition level. Value in health care can be 
calculated by dividing health outcomes by the costs encountered.3,4 
Four key components need to be addressed to achieve health value 
improvement: [1] accurate measurement of health outcomes and 
associated costs; [2] transparent outcome reporting with a classifi-
cation of performance level [eg excellent, good, fair, poor]; [3] sub-
sequent improvement of care delivery in a coordinated care setting 
organized around a single disease; and [4] payment reform to create 
the proper incentives for healthcare participants [Figure 2]. We will 
now discuss the rationale to use those four individual key VBHC 
components.
2.1 Measurement of value
To measure value in health care, both health outcomes [ie quality] 
and costs will need to be measured accurately. We will start by dis-
cussing the general theory on different ways to measure quality of 
care and outcomes in health care, and we will also discuss specific 
measures used in IBD. Thereafter, we will discuss costs measurement 
and one particularly useful method: time-driven activity-based cost-
ing [TDABC].
2.1.1 Quality
Quality of care can be assessed using structure, process, or outcome 
measures.5 A structural measure is related to the structure of the care 
delivery, for example, the number of gastroenterologists that work 
in a hospital. Process measures are related to the process of care 
delivery, for example, the percentage of patients that were tested for 
tuberculosis prior to starting an anti-TNFα agent. Outcome meas-
ures are related to the outcomes of the delivered care, for example 
the quality of life of a patient after a certain procedure. Structure 
measures are usually easy to measure but are generally poorly cor-
related with outcomes. Outcome measures, on the other hand, are 
what matter most to the patient. However, it can take a long time to 
assess outcomes, especially in chronic disease management, which 
generates delays in quality reporting. Process measures are easier to 
measure and represent the medical practice well. However, process 
measures should be closely correlated with outcomes in order to be 
meaningful.5,6
To measure health value, Porter7 proposes always measuring 
value around what is important to the patient. Outcomes, or results, 
are what count to patients and therefore he proposes to measure 
value based on achieved results—instead of using surrogate markers 
such as structure and process measures. However, whereas health 
outcomes should be used to assess value, process measures can be 
very useful to improve internal processes. Porter proposes measuring 
outcomes in three tiers: [1] health status achieved or retained; [2] the 
quality and duration of the recovery process; and [3] the sustainabil-
ity of the achieved health status.7
Additionally, the use of patient-reported outcomes [PROs] is 
an expanding field. The U.S. Food and Drug Administration [FDA] 
requires the use of validated PROs in clinical trials for drugs and 
medical device labeling.8 In 2004, the National Institutes of Health 
[NIH] launched the Patient Reported Outcomes Measurement 
Information System [PROMIS] initiative [www.nihpromis.gov]. This 
initiative aims to support progress in clinical research by building 
and validating common item banks of PROs that measure symp-
toms and outcomes applicable to a wide variety of diseases. This 
will facilitate straightforward interpretation of clinical trial data and 
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Figure 1. Healthcare data for the USA and four European countries. [a] Growth in health expenditure as % of gross domestic product [GDP] between 2002 and 











Figure  2. The four components of value-based health care represented in 
a positive feedback loop on the provider level, which can be accelerated 
by rewarding high value care on a regulatory level: [1] measure value [ie 
outcomes and costs]; [2] report and benchmark outcomes against other 
providers; [3] improve the care delivery process based on observed 
outcomes; and [4] reward high-value care.
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IBD quality measures have been developed by the American 
Gastroentrerology Association [AGA] in conjunction with the 
Crohn’s and Colitis Foundation America [CCFA], in 2011.10 
These are 10 process quality indicators [Qis] related to adherence 
to IBD practice guidelines, consisting of eight outpatient Qis and 
two inpatient Qis. Additionally the CCFA developed a separate set 
of 10 process indicators, of which five overlap with the AGA Qi 
set. A set of 10 outcome measures was developed by the CCFA as 
well and include corticosteroid use, hospitalizations and emergency 
room [ER] visits, productivity, quality of life, malnutrition, anemia, 
night-time bowel movements or leakage, incontinence, and narcotics 
use.6 Within the PROMIS framework a gastrointestinal [GI] symp-
tom bank was developed as well. The GI symptom bank consists of 
scales applicable to both patients with a GI disease and to the gen-
eral population. GI symptoms are measured in seven domains: gas/
bloating flatulence, nausea/vomiting, diarrhea, constipation, bowel 
incontinence/soilage, heartburn/reflux, and disrupted swallowing.11
At UCLA we are currently measuring all outcomes relevant to 
patients: disease control, quality of life [QoL], and [work] productiv-
ity.12 All three are used to: [1] monitor achieved outcomes [tier 1]; [2] 
estimate the time to recovery and the level of discomfort during flares 
[tier 2]; and [3] measure relapse rate [tier 3]. All outcomes are assessed 
on a regular basis to establish the performance of the implemented 
care program as well as to allow for early intervention in case of dis-
ease progression. Specific care scenarios with different frequencies of 
outcome monitoring are allocated based upon individual risk profiles. 
In addition, the AGA process Qis are tracked internally in order to 
identify areas for process improvement. [Ho et al., unpublished data].
2.1.2 Costs
For accurate value calculations, costs need to be measured in great 
detail. In most hospitals, accounting systems are designed for reim-
bursement purposes. Hence, costs are calculated using the charges on 
individual line items and do not always directly correlate with actual 
costs.13 To truly understand what the costs of a treatment process 
are, the Time-Driven Activity-Based Costing [TDABC] method can 
be used. This method calculates costs of a care process based on the 
amount of time spent for every step in the care process. This time is 
then multiplied with the costs per time-unit of the resources [eg per-
sonnel, space, equipment] involved.14 The use of TDABC offers the 
benefit of accurate cost measurement, and is simultaneously a way 
to get insight into how to make care delivery more cost-effective. 
TDABC will help hospitals identify areas in the care process that can 
be delivered more efficiently, estimate the financial benefits of task 
differentiation between different providers, and calculate return on 
investment in quality improvement.14
TDABC pilots have been run in a variety of centers in Belgium,15,16 
at the Cleveland clinic [USA],17 University of California Los Angeles 
[USA],18 the Boston Children’s Hospital [USA],19 and the University 
of Calgary [Canada].20 The Belgian study estimated costs using 
TDABC in five outpatient clinics and reported improvements in 
operations based on TDABC results. Through internal benchmarking 
times for procedure steps between different departments, more effec-
tive methods were identified.16 The Cleveland Clinic used TDABC to 
map and cost two heart valve procedures. They were able to estimate 
accurate costs for each of the processes and found that calculated 
costs were approximately 10% lower than the costs calculated using 
the administrative data. In addition, the TDABC method helped them 
to identify redundancy in their processes, to reassign tasks in order to 
have everyone perform tasks at the top of their license, and to get a 
closer insight on non-billable activities.17 Using TDABC, the Boston 
Children’s hospital was able to decrease total visit time for plagioce-
phalic care by 19.9% [7:29 minutes] due to workflow improvements. 
Costs increased by 7.7% [US$8.22] per visit, but this was offset by 
the additional time available to see two extra patients per day.19 The 
UCLA department of Neurosurgery reports similar advantages using 
a continuous cycle of identification of variation, identifying the most 
cost-effective solution, and process improvement.18
At UCLA, we started to use the TDABC model to assess the costs 
associated with Qi implementation in clinic. We identified seven types 
of personnel involved in the Qi process in the GI clinic. For the IBD 
clinic, total costs for general IBD measures including vaccinations, 
documentation of disease activity, and tobacco use, were US$80.33; 
addition of bone loss assessment increased the costs to US$91.41; and 
addition of process costs for checking hepatitis B and tuberculosis prior 
to anti-TNFa therapy initiation was US$108.76 [Ho et al., unpublished 
data]. In future efforts, radiology costs and lab costs will be estimated 
using TDABC as well, for a more comprehensive value calculation.
2.2 Outcome reporting
Outcome registries are thought to increase value by driving patient 
and physician improvements. If outcome registries are publicly avail-
able, patients can choose the best medical practice for their care and 
avoid physicians with poor outcomes. On the other hand, registries 
offer the potential for providers to benchmark themselves against other 
practitioners and identify areas where they are lagging behind, and 
subsequently improve. The effect of health registries in Sweden was 
recently analyzed in depth by the Boston Consultancy Group [BCG]. 
Sweden has had an interest in tracking outcomes since the 1800s and 
implemented official registries covering a broad array of diseases in 
the 1970s. Sweden’s health outcomes are among the best in Europe, 
whereas costs are around average. BCG found that while reporting 
on acute lymphoblastic leukemia [ALL] survival rates, ALL treatments 
dramatically improved with an increase in survival rates from 12% in 
the early 1970s to 89% in 2005. Similarly, side effects from cataract 
surgery decreased dramatically. Though no comparative studies were 
done, some indications of the impact of disease registries were found. 
Two hospitals with low outcomes in survival rates after a myocardial 
infarction changed their practice after public reporting and achieved 
a 50% reduction in 30-day mortality within 2 years of the report.21
Disease-specific examples are identified as well. A steady rise in 
in-vitro fertilization [IVF] success rates was observed in the USA, 
after the Centers for Disease Control and Prevention started pub-
licly reporting IVF outcomes. This can be illustrated by a decrease 
in the number of IVF cycles entailing the transfer of three or more 
embryos from 83% to 35%.22 Similarly, in the cardiac surgery field, 
a decrease was observed in mortality rates after coronary artery 
bypass graft [CABG] surgery from 3.2% in 1996 to 2.2% in 2005 
in the presence of a public reporting system.23 In a blog post for the 
Harvard Business Review, Toby Cosgrove, Chief Executive Officer of 
the Cleveland Clinic, reported a decrease in infections after surgery 
by 40% and a decrease of urinary tract infections by 50%, after 
reporting of provider performance data.24 In Europe, several coun-
tries have implemented registries as well, measuring quality indica-
tors, outcomes, and/or patient satisfaction data.25
Due to the nature of the available data, it remains hard to assess 
whether observed effects are a direct cause of the registries or of pro-
gress in the medical sciences. A literature review from the U.S. Agency 
for Healthcare Research and Quality, analyzing 97 qualitative and 101 
quantitative studies, found overall substantial evidence that reporting 
leads to improvements in the quality measures and moderate evidence 
that reporting might lead to a reduction in mortality. They also showed 
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that reporting requirements mainly drive changes in physician behav-
ior, rather than in patient behavior such as choosing a different doc-
tor based on reports.26 Furthermore, there is emerging evidence that 
introduction of public reporting systems leads to a reduction in costs. 
A recent retrospective controlled study found a decrease of 13.7% in 
CABG prices and 11.4% in percutaneous transluminal intervention 
[PTI] prices after introduction of a public reporting system.27
IBD outcome registries are being built as well. As previously 
mentioned, the AGA developed a set of 10 Qi measures for IBD 
specifically.10 Reporting of eight of the 10 AGA quality measures to 
the Centers for Medicare and Medicaid Services [CMS] is required 
in specific conditions in the USA, and reporting of those measures 
to CMS is directly linked to reimbursements.18 In 2013, the British 
Society of Gastroenterology launched a national IBD specific registry 
as well, which includes information on number of patients, admis-
sions, surgeries, and medication use for national benchmarking.28
2.3 Care coordination
In order to deliver high-value care, the most accurate treatment 
should be chosen for the right patient, at the right location, at the 
right time. Practice guidelines have been installed by many physician 
associations. However, guidelines are not followed consistently. In a 
2010–2012 US nationwide analysis, we showed that 42% of Crohn’s 
disease patients were prescribed 5-aminosalicylic acid [5-ASA] even 
though not supported by current guidelines, and steroid-sparing med-
ication was prescribed infrequently, whereas 9% of all IBD patients 
used long-term [> 3 months] steroids.29 Reasons for guideline non-
adherence could be a lack of incentives for guideline adherence, lack 
of access to guidelines, or a lack of trust towards guidelines.30
Care coordination has been proposed to be a key need in order to 
improve care quality. Care coordination includes the use of evidence-
based care pathways by a multidisciplinary care team ensuring con-
tinuity of care and engaging the patient in the care process.31 A study 
in an insurance claims database, analyzing continuity of care defined 
as the percentage of visits with the same provider, showed that mod-
erate improvements in care continuity in patients with chronic dis-
eases were associated with substantial improvements in outcomes 
and decreases in complications and costs.32 A review assessing the 
effect of care coordination systems in chronic disease management 
found positive effects on quality of life, functional status and health 
outcomes, satisfaction scores, guideline adherence, and compli-
ance.31 Additionally, routine collection of PROs was shown to be 
beneficial for patient-provider communication, and for monitor-
ing of treatment response and detecting unrecognized problems in 
cancer patients.33 Furthermore, it is shown that healthcare systems 
organized around primary care are associated with lower healthcare 
expenditures and that systems with a weak primary care infrastruc-
ture are associated with worse health outcomes.34 The US patient-
centered medical home [PCMH] is a model that explores this further. 
PCMH can be described as a model for care that includes primary 
care access, comprehensiveness, care coordination, and continuity of 
care. Hundreds of pilots have been initiated over the USA and the 
first controlled results suggest improved outcomes, reduced health 
care utilization, and cost savings, due to initiation of a PCMH.35
For IBD specifically, the Royal Adelaide hospital in Australia found 
a significant decrease in costs and fewer hospitalizations after intro-
duction of a coordinated care infrastructure in a controlled study.36 
Hospitals in the UK, Italy, The Netherlands, Canada, and Austria have 
been working with integrated care models as well, though no outcomes 
are presented.37 The UCLA Center for IBD, launched in 2012, uses 
an approach that combines all components of coordinated care and 
outcome measurements. Multidisciplinary care pathways for IBD were 
developed and implemented, which include evidence-based practice 
management, task differentiation and coordination between provid-
ers, and collection of outcomes. PROs are collected routinely using a 
patient-facing mobile application, which is used for patient monitoring 
and outcome reporting. This process is supported by a solid IT infra-
structure, with a provider portal and a patient-facing mobile applica-
tion [UCLA eIBD, available for iOS and Android]. This infrastructure 
also facilitates patient-provider communication and education, and 
offers wellness programs. Healthcare providers can evaluate their 
patients’ outcomes, health care utilization, and associated costs.12,38 
A controlled analysis using a payer database of 49 UCLA IBD Center 
patients versus 245 IBD controls showed a significant decrease in cor-
ticosteroid use from 31% to 12%, and 1.3–3.4 times more frequent 
biomarker testing. Non-significant decreases in emergency department 
[ED] visits [75% decrease], hospitalizations [89% decrease], and office 
visits [25% decrease] were observed as well.39
2.4 Payment reform to reward value
Value-based insurance design [VBID] is an approach to use insurance 
models that reward high-value care. Initial efforts were mainly focussed 
on cost-sharing strategies, whereas the value component has only been 
added in pilots more recently. In the famous RAND health insurance 
experiment [1974–1982], it was shown already that health care is 
affected by a certain price elasticity, which is shown by a higher demand 
for medical care if copayments for patients are lower.40 However, non-
specific cost-sharing strategies target necessary care as well as unneces-
sary care, which is why the introduction of value in insurance designs 
is important. The first area in which VBID was implemented was the 
prescription drug arena. Incentives can be targeted to patients, health-
care professionals, or both. Throughout the Organisation for Economic 
Cooperation and Development [OECD] member countries, different 
approaches are already being utilized by governments to stimulate 
cost-effective drug use using cost sharing strategies. Strategies used to 
incentivize patients include lowering co-payments or waiving the maxi-
mum allowed payment cap for essential medications or generic variants 
of drugs. Strategies aimed at physicians include compulsory guideline-
based prescribing and benchmarking against other physicians, coupled 
with either financial penalties or rewards.41
Patient-targeted approaches include policies that, for example, 
lower co-payments for high-value drugs specifically, to improve 
patient adherence. A 2013 paper reviewing 13 studies assessing the 
effect of reduced co-payments found an increase in quality but no 
reduction in health expenditure.42 The majority of studies assessed the 
effect of reducing co-payments on diabetes and hypertension medica-
tion. Reductions of 25-100% in co-payments were found to increase 
adherence by on average 3% after 1 year. As expected, an increase in 
prescription drug expenditure was observed for insurers, but overall 
health expenditure was generally not affected. Two studies evaluated 
healthcare utilization and found reduction in office visits, ED visits, 
and hospitalizations. Furthermore, two studies that included disease 
management with the VBID did observe decreased overall expen-
ditures.42 Another 2014 review, incorporating 10 studies [of which 
seven overlap with the previous review], had comparable conclu-
sions and observed an improvement in medication adherence from 
2–5 percentage points and lack of evidence for changes in expendi-
ture, outcomes, or healthcare utilization.43 A more in-depth analysis 
of 76 VBID plans introduced by a large pharmacy benefit manager 
found increased adherence in VBID plans that offered more gener-
ous benefits, targeted high-risk patients, had wellness programs, and 
made benefits available only for mail orders. Plans including disease 
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management programs had higher adherence rates, but interestingly 
enough, disease management programs had a consistently negative 
effect on adherence improvements after introduction of VBID. The 
authors conclude this effect might be explained by the fact that VBID 
and disease management both aim for the same goal, or because base-
line adherence was relatively high in those programs and the effect 
we observe is a ‘ceiling’ effect.44 A third review assessing the effect of 
drug insurance cost-sharing strategies for patients with cardiovascu-
lar-related chronic diseases confirmed positive effects on adherence 
rates, although effects on outcomes remained unclear.45
Non-pharmacy patient-targeted VBID approaches, mostly tar-
geted at preventive services, are thought to be of high value to the 
healthcare system. The 2010 U.S. Patient Protection and Affordable 
Care Act [ACA] requires coverage without cost-sharing of certain 
preventive health services. Among these services are women’s pre-
ventive health services. These include vaccinations, screening, and 
preventive treatments for certain risk groups.46,47 Inclusion of sec-
ondary preventive services is theoretically of high value as well. 
However, an analysis from the University of Michigan’s Center for 
Value Based Insurance Design estimated that addition of certain 
secondary preventive services in high-deductible health plans would 
lead to a 5.1–5.6% increase in premiums. Nevertheless, over the long 
term, including those services is thought to increase health value.48
Programs targeting treating physicians are implemented as well. 
Initial efforts to incentivize performance and accountability among pro-
viders are pay for performance programs [P4P], where physicians are 
rewarded or penalized when reaching certain quality targets—which 
are usually process measures. Additionally, the ACA allows healthcare 
providers to form ‘Accountable Care Organizations’ [ACOs]. ACOs 
are provider organizations organized around primary care, in which 
all participants are accountable for the quality and outcomes of care. 
The provider group is eligible to share in healthcare savings with the 
insurers when they reach certain quality targets. These quality targets 
are focussed around four domains: patient/caregiver experience, care 
coordination and patient safety, preventive health, and care for at-
risk populations.49 Similarly, in different European countries payment 
reforms are being pursued, including rewards for the introduction of 
disease management programs in Germany, and bundled payments for 
episodes of care in The Netherlands.50 The effect of P4P programs on 
costs and outcomes is unclear because only few good quality studies 
are available.51 Studies mostly show either a null effect or a marginal 
positive effect. The experience with ACOs and bundled payments incor-
porating quality incentives is still limited. Reported results on quality 
measures, outcomes, and costs are mixed, and nine out of 32 CMS ACO 
contracts were discontinued.51 Best results are thought to come from 
bundled payments for episodes of care coupled to quality targets.4
In the field of gastroenterology, there is interest in implementation 
of VBID as well. Saini et al. suggest, as an example, the introduction 
of higher co-payment for upper endoscopies when the indication is 
gastroesophageal reflux disease [GERD] than when the indication 
is dysphagia.52 We propose to introduce VBID in a comprehensive 
structure that incentivizes all stakeholders involved in IBD care to 
utilize high-value care, which includes incentives for insurers, phy-
sicians, and patients. Physicians should be rewarded for good per-
formance on a disease-specific level. Using a cost-sharing insurance 
design, physicians with better outcomes should be at low financial 
risk, while having more financial benefits, whereas physicians with 
worse outcomes would have higher risks with lower benefits. This 
would result in a model in which savings with excellent outcomes 
are rewarded with a large percentage of shared savings for the pro-
vider, savings with suboptimal outcomes are only rewarded with a 
small percentage of the savings, and savings with bad outcomes are 
not rewarded at all. On the other side of the spectrum, physicians 
with high costs and bad outcomes would be penalized by a high per-
centage of sharing in financial losses, high cost with better outcomes 
should only be penalized with a smaller percentage in shared losses, 
and in cases where the provider achieves excellent outcomes, financial 





















Figure 3. Proposed value-based insurance design [VBID] mechanism. Providers are incentivized to deliver high-value care by increases in shared savings when 
delivering better outcomes at lower than expected costs [segment A]. Conversely, providers are disincentivized to deliver low-value care by increases in shared 
losses delivering worse outcomes at higher than expected costs [segment B]. When delivering better outcomes at higher than expected costs, shared losses will 
decrease [segment C], whereas when delivering worse outcomes at lower than expected costs, shared savings will decrease [segment D]. Benchmark outcomes 
and costs are risk-adjusted based on the population mix.
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risk-adjusted based on the population mix. This structure is similar to 
the structure used by the second arm of the Medicare Shared Savings 
Program.49 Furthermore, patients should be incentivized to partici-
pate in their care. At UCLA, we calculate individual participation 
scores based on whether patients participate in patient education and 
home monitoring and comply with scheduled visits, procedures, and 
tests. We propose that patients should be financially rewarded based 
on their participation score, which will stimulate better outcomes.
3. Conclusion
The introduction of VBHC is inevitable, but approaches on how to 
achieve value in health care differ. The key concepts include: [1] measure-
ment of outcomes and costs; [2] benchmarking of outcomes and costs; 
[3] implementation of a value-based clinical system; and [4] the introduc-
tion of incentives for delivery of value care. Although the introduction of 
incentives is mainly in the hands of regulators and insurers, the first three 
concepts can be driven from within the medical community. Payment 
reforms are emerging worldwide, and the medical community should be 
closely involved in the development of these contracts. By implementing 
the first three components into their practices, providers can improve 
their care delivery processes and ensure high-value care delivery. These 
efforts will be rewarded financially as well after the formal introduction 
of VBID programs. Results on the effects of value-based approaches are 
still very limited, but many pilot programs are running and initial results 
are encouraging. We described the approach at UCLA as guidance for 
implementation of VBHC for care delivery.
Acknowledgments
This work was supported by institutional funds for projects relevant to the 
UCLA Center for Inflammatory Bowel Diseases.
All authors have been involved in the conception and design of the review. 
WKD drafted the article; EE and DWH revised the manuscript critically for 
important intellectual content. All authors approved of the final version of the 
manuscript to be submitted. No writing assistance was utilized in the produc-
tion of this manuscript.
Conflict of interest statement.
WKD declares no conflict of interest. EE and DWH have a patent Value-Based 
Health Care Management Systems and Methods issued to UCLA.
References
 1. World Bank. Health Nutrition and Population Statistics. http://databank.
worldbank.org/data/databases.aspx Accessed January 14, 2015.
 2. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA 
2012;307:1513–6.
 3. Porter ME, Teisberg EO. Redefining competition in health care. Harv Bus 
Rev 2004;82:64–76, 136.
 4. Porter ME, Lee TH. The strategy that will fix health care. Harv Bus Rev 
2013;91:24.
 5. Brook RH, McGlynn EA, Cleary PD. Quality of health care. Part 2: meas-
uring quality of care. N Engl J Med 1996;335:966–70.
 6. Melmed GY, Siegel CA. Quality improvement in inflammatory bowel dis-
ease. Gastroenterol Hepatol 2013;9:286–92.
 7. Porter ME. What is value in health care? N Engl J Med 2010;363:2477–81.
 8. U.S. Department of Health and Human Services, Food and Drug Adminis-
tration. Guidance for Industry. Patient-Reported Outcome Measures: Use 
in Medical Product Development to Support Labeling Claims. Washing-
ton, DC: U.S. Department of Health and Human Services; 2009.
 9. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measure-
ment Information System [PROMIS] developed and tested its first wave of 
adult self-reported health outcome item banks: 2005–2008. J Clin Epide-
miol 2010;63:1179–94.
 10. American Gastroenterological Association. Adult Inflammatory Bowel 
Disease Physician Performance Measures Set. 2011. http://www.gastro.
org/practice/quality-initiatives/IBD_Measures.pdf Accessed January 8, 
2015.
 11. Spiegel BM, Hays RD, Bolus R, et al. Development of the NIH Patient-
Reported Outcomes Measurement Information System [PROMIS] gastro-
intestinal symptom scales. Am J Gastroenterol 2014;109:1804–14.
 12. Hommes DW, Esrailian E. How does a gastroenterologist demon-
strate value? Clin Gastroenterol Hepatol 2014 Oct 28. pii: S1542-
3565(14)01575-4. doi: 10.1016/j.cgh.2014.10.024. [Epub ahead of print.]
 13. Mercier G, Naro G. Costing hospital surgery services: the method matters. 
PLoS One 2014;9:e97290.
 14. Kaplan RS, Porter ME. How to solve the cost crisis in health care. Harv 
Bus Rev 2011;89:46–61.
 15. Lievens Y, Obyn C, Mertens AS, Van Halewyck D, Hulstaert F. Stereotactic 
body radiotherapy for lung cancer: How much does it really cost? J Thorac 
Oncol 2014 Nov 7. PMID: 25376514. [Epub ahead of print.]
 16. Demeere N, Stouthuysen K, Roodhooft F. Time-driven activity-based 
costing in an outpatient clinic environment: development, relevance and 
managerial impact. Health Policy 2009;92:296–304.
 17. Donovan CJ, Hopkins M, Kimmel BM, Koberna S, Montie CA. How 
Cleveland Clinic used TDABC to improve value. Healthc Financ Manage 
2014;68:84–8.
 18. McLaughlin N, Burke MA, Setlur NP, et  al. Time-driven activity-based 
costing: a driver for provider engagement in costing activities and redesign 
initiatives. Neurosurg Focus 2014;37:E3.
 19. Inverso G, Lappi MD, Flath-Sporn SJ, Heald R, Kim DC, Meara JG. 
Increasing value in plagiocephaly care: a time-driven activity-based cost-
ing pilot study. Ann Plast Surg 2013 Dec 5.  PMID: 24317242. [Epub 
ahead of print.]
 20. Au J, Rudmik L. Cost of outpatient endoscopic sinus surgery from the per-
spective of the Canadian government: a time-driven activity-based costing 
approach. Int Forum Allergy Rhinol 2013;3:748–54.
 21. Larsson S, Lawyer P, Silverstein MB. From Concept to Reality. Putting 
Value-Based Health Care into Practice in Sweden. London: Boston Con-
sulting Group; 2010.
 22. Adashi EY, Wyden R. Public reporting of clinical outcomes of assisted 
reproductive technology programs: implications for other medical and 
surgical procedures. JAMA 2011;306:1135–6.
 23. Steinbrook R. Public report cards cardiac surgery and beyond. N Engl J 
Med 2006;355:1847–9.
 24. Cosgrove T. Value-based health care is inevitable and that’s good. Harv 
Bus Rev 2013. https://hbr.org/2013/09/value-based-health-care-is-inevita-
ble-and-thats-good Accessed 8 January 2014.
 25. Rodrigues R, Trigg L, Schmidt AE, Leichsenring K. The public gets what 
the public wants: experiences of public reporting in long-term care in 
Europe. Health Policy 2014;116:84–94.
 26. Totten AM, Wagner J, Tiwari A, O’Haire C, Griffin J, Walker M. Closing 
the quality gap: revisiting the state of the science. Vol 5: public reporting 
as a quality improvement strategy. Evid Rep Technol Assess 2012;208:1–
645.
 27. Dor A, Encinosa WE, Carey K. Medicare’s hospital compare quality 
reports appear to have slowed price increases for two major procedures. 
Health Aff [Millwood] 2015;34:71–7.
 28. U.K. IBD registry. Data entry options. http://www.ibdregistry.org.uk/data-
entry-options Accessed 14 January 2015.
 29. van Deen WK, van Oijen MG, Myers KD, et al. A nationwide 2010–2012 
analysis of U.S.  health care utilization in inflammatory bowel diseases. 
Inflamm Bowel Dis 2014;20:1747–53.
 30. Kenefick H, Lee J, Fleishman V. Improving Physician Adherence to Clinical 
Practice Guidelines: Barriers and Strategies for Change. Cambridge, MA: 
New England Healthcare Institute; 2008.
Value-Based Health Care In IBD 427
 31. Ouwens M, Wollersheim H, Hermens R, Hulscher M, Grol R. Integrated 
care programmes for chronically ill patients: a review of systematic 
reviews. Int J Qual Health Care 2005;17:141–6.
 32. Hussey PS, Schneider EC, Rudin RS, Fox DS, Lai J, Pollack CE. Continuity 
and the costs of care for chronic disease. JAMA Intern Med 2014;174:742–8.
 33. Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine 
collection of patient reported outcome measures on patients, providers 
and health organisations in an oncologic setting. BMC Health Serv Res 
2013;13:211.
 34. Starfield B, Shi L. Policy relevant determinants of health: an international 
perspective. Health Policy 2002;60:201–18.
 35. Arend J, Tsang-Quinn J, Levine C, Thomas D. The patient-centered medi-
cal home: history, components, and review of the evidence. Mt Sinai J Med 
2012;79:433–50.
 36. Sack C, Phan VA, Grafton R, et  al. A chronic care model significantly 
decreases costs and healthcare utilisation in patients with inflammatory 
bowel disease. J Crohns Colitis 2012;6:302–10.
 37. Mikocka-Walus AA, Andrews JM, Bernstein CN, et al. Integrated models 
of care in managing inflammatory bowel disease: a discussion. Inflamm 
Bowel Dis 2012;18:1582–7.
 38. Van Deen WK, Choi JM, Inserra EK, et al. The development and evalua-
tion of coordinated care pathways for inflammatory bowel diseases. Gas-
troenterology 2014;146(Suppl 1):S–376.
 39. Van Deen WK, Ozbay AB, Skup M, et al. The impact of a value-based 
health program for inflammatory bowel disease management on healthcare 
utilization. J Crohns Colitis 2015;9(suppl 1):S123–4.
 40. Manning WG, Rand Corporation, United States Department of Health and 
Human Services. Health Insurance and the Demand for Medical Care: Evi-
dence From a Randomized Experiment. Santa Monica, CA: Rand; 1988.
 41. Barnieh L, Clement F, Harris A, et al. A systematic review of cost-sharing 
strategies used within publicly-funded drug plans in member countries of 
the Organisation for Economic Co-Operation and Development. PLoS 
One 2014;9:e90434.
 42. Lee JL, Maciejewski M, Raju S, Shrank WH, Choudhry NK. Value-based 
insurance design: quality improvement but no cost savings. Health Aff 
[Millwood] 2013;32:1251–7.
 43. Tang KL, Barnieh L, Mann B, et al. A systematic review of value-based 
insurance design in chronic diseases. Am J Manag Care 2014;20: 
e229–41.
 44. Choudhry NK, Fischer MA, Smith BF, et al. Five features of value-based 
insurance design plans were associated with higher rates of medication 
adherence. Health Aff [Millwood] 2014;33:493–501.
 45. Mann BS, Barnieh L, Tang K, et al. Association between drug insurance 
cost sharing strategies and outcomes in patients with chronic diseases: a 
systematic review. PLoS One 2014;9:e89168.
 46. U.S. Departments of Treasury; Labor; and Health and Human Services. 
Interim final rules for group health plans and health insurance issuers 
relating to coverage of preventive services under the Patient Protection 
and Affordable Care Act. Federal Register 2010:4172660.
 47.  U.S. Departments of Treasury; Labor; and Health and Human Services. 
Coverage of certain preventive services under the affordable care act. Fed-
eral Register 2014:51092101.
 48. Fendrick AM, Cliff EQ, McKellar MR, et al. Health Savings Account Eligi-
ble High Deductible Health Plans: Updating the Definition of Prevention. 
White Paper. Ann Arbor, MI: University of Michigan’s Center for Value-
based Insurance Design; 2014.
 49. Medicare Program; Medicare Shared Savings Program: Accountable Care 
Organizations. Federal Register 2011:4172660.
 50. Nolte E, Knai C, Hofmarcher M, et  al. Overcoming fragmentation in 
health care: chronic care in Austria, Germany and The Netherlands. 
Health Econ Policy La 2012;7:125–46.
 51. Damberg C, Sorbero ME, Lovejoy SL, et al. Measuring success in health 
care value-based purchasing programs: summary and recommendations. 
Santa Monica, CA: RAND Corporation; 2014 
 52. Saini SD, Fendrick AM. Value-based insurance design: implications for 
gastroenterology. Clin Gastroenterol Hepatol 2010;8:767–9.
